Clinical Trial Update: mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases [Phase 3]

View source ↗

Summary

Phase 3 trial comparing mFOLFOXIRI+Bevacizumab versus mFOLFOX6+Bevacizumab in patients with RAS-mutant unresectable colorectal liver-limited metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Liver Metastases

Drugs mentioned

• mFOLFOX6+Bevacizumab
• mFOLFOXIRI+Bevacizumab

Snippet

Sponsor: Fudan University | Conditions: Colorectal Carcinoma, Liver Metastases | Phase 3 | Status: UNKNOWN